A Narrative Review of the Diagnostic Performance of Non-Invasive Scores for Predicting Fibrosis in MAFLD
Downloads
Background & aim: The burden of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) is increasing, with an estimated prevalence of 32.4% globally. Although most patients present with simple steatosis, some progress to advanced fibrosis, cirrhosis, and hepatocellular carcinoma. Non-invasive scores offer a promising alternative to liver biopsy for fibrosis staging. This narrative review aims to compare the diagnostic performance of non-invasive scores for in detecting fibrosis in patients with MAFLD, with a focus on identifying the most accurate and reliable score.
Methods: This narrative review included studies with histologically confirmed fibrosis staging. The primary outcome was the overall diagnostic accuracy of each score in predicting significant fibrosis (F2-F4) and advanced fibrosis (F3-F4). Secondary outcomes included sensitivity, specificity, and positive and negative predictive values.
Results & Conclusion: Our analysis included a total of 11 studies with 5761 patients. The overall diagnostic performance for predicting advanced fibrosis was highest for Magnetic Resonance Elastography (MRE), followed by Transient Elastography (VCTE). In predicting significant fibrosis, Hepamet Fibrosis Score (HFS) demonstrated the highest performance. Significant variation was observed across studies, which was partially explained by differences in the prevalence of advanced fibrosis and the specific thresholds utilized for each score.
Downloads
Guo, Z., Wu, D., Mao, R. et al. Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021. Sci Rep 15, 7083 (2025). https://doi.org/10.1038/s41598-025-91312-5
Li QQ, Xiong YT, Wang D, Wang KX, Guo C, Fu YM, Niu XX, Wang CY, Wang JJ, Ji D, Bai ZF. Metabolic syndrome is associated with significant hepatic fibrosis and steatosis in patients with nonalcoholic steatohepatitis. ILIVER. 2024 Apr 24;3(2):100094. doi: 10.1016/j.iliver.2024.100094. PMID: 40636476; PMCID: PMC12212728.
Leung PB, Davis AM, Kumar S. Diagnosis and Management of Nonalcoholic Fatty Liver Disease. JAMA. 2023;330(17):1687–1688. doi:10.1001/jama.2023.17935
Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F and Li H (2021) Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front. Med. 8:761538. doi: 10.3389/fmed.2021.761538
Martinou, E.; Pericleous, M.; Stefanova, I.; Kaur, V.; Angelidi, A.M. Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics2022, 12, 407. https://doi.org/10.3390/diagnostics12020407
Papastergiou V, Tsochatzis E, Burroughs AK. Non-invasive assessment of liver fibrosis. Ann Gastroenterol. 2012;25(3):218-231. PMID: 24714123; PMCID: PMC3959378.
Lee JH, Joo I, Kang TW, Paik YH, Sinn DH, Ha SY, et al. Deep learning with ultrasonography: automated classification of liver fibrosis using a deep convolutional neural network. Eur Radiol. 2020;30:1264–73. doi: 10.1007/s00330-019-06407-1.
Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32–36. doi: 10.1002/hep.21669.
Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–854. doi: 10.1002/hep.21496.
Loaeza-del-Castillo, Aurora, Francisco Paz-Pineda, Edgar Oviedo-Cárdenas, Francisco Sánchez-Ávila, and Florencia Vargas-Vorácková. 2008. “AST to Platelet Ratio Index (APRI) for the Noninvasive Evaluation of Liver Fibrosis.” Annals of Hepatology 7: 350–57. https://doi.org/10.1016/S1665-2681(19)31836-8.
Huang C, Seah JJ, Tan CK, Kam JW, Tan J, Teo EK, et al. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 2021;45:101528. doi: 10.1016/j.clinre.2020.08.006.
Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704–1713. doi: 10.1053/j.gastro.2004.08.052.
Higuera-de-la-Tijera F, Córdova-Gallardo J, Buganza-Torio E, Barranco-Fragoso B, Torre A, Parraguirre-Martínez S, Rojano-Rodríguez ME, Quintero-Bustos G, Castro-Narro G, Moctezuma-Velazquez C. Hepamet Fibrosis Score in Nonalcoholic Fatty Liver Disease Patients in Mexico: Lower than Expected Positive Predictive Value. Dig Dis Sci. 2021 Dec;66(12):4501-4507. doi: 10.1007/s10620-020-06821-2. Epub 2021 Jan 11. PMID: 33428035.
Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004;3:8. doi: 10.1186/1476-5926-3-8.
Cichoż-Lach H, Celiński K, Prozorow-Król B, Swatek J, Słomka M, Lach T. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit. 2012 Dec;18(12):CR735-40. doi: 10.12659/msm.883601. PMID: 23197236; PMCID: PMC3560810.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797–835. doi: 10.1097/HEP.0000000000000323.
Anstee QM, Lawitz EJ, Alkhouri N, Wong VW-S, Romero-Gomez M, Okanoue T, et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials. Hepatology. 2019;70:1521–30. doi: 10.1002/hep.30842.
Itakura J, Kurosaki M, Setoyama H, Simakami T, Oza N, Korenaga M, et al. Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis. J Gastroenterol. 2021;56:470–8. doi: 10.1007/s00535-021-01782-3.
Xu X-Y, Wang W-S, Zhang Q-M, Li J-L, Sun J-B, Qin T-T, et al. Performance of common imaging techniques vs serum biomarkers in assessing fibrosis in patients with chronic hepatitis B: a systematic review and meta-analysis. World J Clin Cases. 2019;7:2022–37. doi: 10.12998/wjcc.v7.i15.2022.
Xu X-Y, Kong H, Song R-X, Zhai Y-H, Wu X-F, Ai W-S, et al. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy. PLoS One. 2014;9:e100182. doi: 10.1371/journal.pone.0100182.
Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61:292–302. doi: 10.1002/hep.27382.
Roh YH, Kang B-K, Jun DW, Lee C, Kim M. Role of FIB-4 for reassessment of hepatic fibrosis burden in referral center. Sci Rep. 2021;11:13616. doi: 10.1038/s41598-021-93038-6.
Moolla A, Motohashi K, Marjot T, Shard A, Ainsworth M, Gray A, et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterol. 2019;10:337–46. doi: 10.1136/flgastro-2018-101155.
McPherson S, Hardy T, Dufour J-F, Petta S, Romero-Gomez M, Allison M, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112:740–51. doi: 10.1038/ajg.2016.453.
Hagström H, Talbäck M, Andreasson A, Walldius G, Hammar N. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J Hepatol. 2020;73:1023–9. doi: 10.1016/j.jhep.2020.06.007.
European Association for the Study of the Liver (EASL) ; European Association for the Study of Diabetes (EASD) ; European Association for the Study of Obesity (EASO) EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–402. doi: 10.1016/j.jhep.2015.11.004.
Graupera I, Thiele M, Serra-Burriel M, Caballeria L, Roulot D, Wong GL-H, et al. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol. 2022;20:2567–76.e6. doi: 10.1016/j.cgh.2021.12.034.
Maroto-García J, Moreno Álvarez A, Sanz de Pedro MP, Buño-Soto A, González Á. Serum biomarkers for liver fibrosis assessment. Adv Lab Med. 2023 Nov 14;5(2):115-130. doi: 10.1515/almed-2023-0081. PMID: 38939201; PMCID: PMC11206202.
Zhao Y, Thurairajah PH, Kumar R, Tan J, Teo EK, Hsiang JC. Novel non-invasive score to predict cirrhosis in the era of hepatitis C elimination: a population study of ex-substance users in Singapore. Hepatobiliary Pancreat Dis Int. 2019;18:143–8. doi: 10.1016/j.hbpd.2018.12.002.
Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, et al.; On Behalf Of The Litmus Systematic Review Team. FibroTest for Evaluating Fibrosis in Non Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:2415.
Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, et al. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Aliment Pharmacol Ther. 2016;44:877–89. doi: 10.1111/apt.13770.
Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, et al. FibroTest for evaluating fibrosis in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis. J Clin Med. 2021;10:2415. doi: 10.3390/jcm10112415.
Ampuero J, Pais R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, et al. Development and validation of Hepamet fibrosis scoring system-A simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis. Clin Gastroenterol Hepatol. 2020;18:216–25.e5. doi: 10.1016/j.cgh.2019.05.051.
Rigor J, Diegues A, Presa J, Barata P, Martins-Mendes D. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population. Postgrad Med. 2022;134:435–40. doi: 10.1080/00325481.2022.2058285.
Higuera-de-la-Tijera F, Córdova-Gallardo J, Buganza-Torio E, Barranco-Fragoso B, Torre A, Parraguirre-Martínez S, et al. Hepamet fibrosis score in nonalcoholic fatty liver disease patients in Mexico: lower than expected positive predictive value. Dig Dis Sci. 2021;66:4501–7. doi: 10.1007/s10620-020-06821-2.
Zambrano-Huailla R, Guedes L, Stefano JT, de Souza aa, Marciano S, Yvamoto E, et al. Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population. Ann Hepatol 2020;19:622–6.
Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–7. doi: 10.1136/gut.2007.146019.
Rosenberg W.M.C., Voelker M., Thiel R., Becka M., Burt A., Schuppan D., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704–1713. doi: 10.1053/j.gastro.2004.08.052.
Vali Y., Lee J., Boursier J., Spijker R., Löffler J., Verheij J., et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2020;73:252–262. doi: 10.1016/j.jhep.2020.03.036.
Glen J., Floros L., Day C., Pryke R. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. BMJ. 2016;354:i4428. doi: 10.1136/bmj.i4428.
Berzigotti A., Tsochatzis E., Boursier J., Castera L., Cazzagon N., Friedrich-Rust M., et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol. 2021;75:659–689. doi: 10.1016/j.jhep.2021.05.025.
Mueller S, Sandrin L. Liver stiffness: a novel parameter for the diagnosis of liver disease. Hepat Med. 2010;2:49-67 https://doi.org/10.2147/HMER.S7394
Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;156:1717–30.
Mariappan YK, Glaser KJ, Ehman RL. Magnetic resonance elastography: a review. Clin Anat 2010;23:497–511.
Copyright (c) 2025 Georgian Scientists
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
